New pages
Jump to navigation
Jump to search
12 March 2025
- 21:3721:37, 12 March 2025 Tenapanor (hist | edit) [4,276 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Tenapanor |aOrAn=a |drugClass=Sodium/Hydrogen Exchanger 3 (NHE3) Inhibitor |indicationType=treatment |indication=irritable bowel syndrome with constipation (IBS-C) in adults. Also it v=can be used for reduction of serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy. |hasBlackBoxWarning=Yes |adverseReactions=Diarrhea (16% in IBS-C patients; 43-53% in CKD patien...")
- 21:2021:20, 12 March 2025 Istradefylline (hist | edit) [4,113 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=istradefylline |aOrAn=an |drugClass=Adenosine A₂A Receptor Antagonist |indicationType=treatment |indication=adult patients with Parkinson's disease (PD) experiencing "off" episodes along with treatment to levodopa/carbidopa |adverseReactions=Dyskinesia (involuntary muscle movements), Hallucinations Insomnia, Nausea, and Constipation. |offLabelAdultGuideSupport=There is limited information regard...")
9 March 2025
- 21:1921:19, 9 March 2025 Ga-68-DOTATOC (hist | edit) [4,233 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Gallium-68 DOTATOC |aOrAn=a |drugClass=radiopharmaceutical diagnostic agent |indicationType=procedure |indication=positron emission tomography (PET) imaging for the localization of somatostatin receptor-positive neuroendocrine tumors (NETs) in adult and pediatric patients. |adverseReactions=Nausea, Vomiting, Flushing, Injection site pain |blackBoxWarningTitle='''<span style="color:#FF0000;">TITLE</...")
- 21:0321:03, 9 March 2025 Lefamulin (hist | edit) [6,506 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Lefamulin |aOrAn=a |drugClass=Pleuromutilin Antibiotic |indicationType=treatment |indication=adults with community-acquired bacterial pneumonia (CABP) caused by susceptible microorganisms. |adverseReactions=injection: administration site reactions, hepatic enzyme elevation, nausea, hypokalemia, insomnia, headache. Oral: diarrhea, nausea, vomiting, hepatic enzyme elevation. |blackBoxWarningTit...")
- 20:4720:47, 9 March 2025 Upadacitinib (hist | edit) [9,728 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Upadacitinib |aOrAn=a |drugClass=Janus Kinase (JAK) Inhibitor |indicationType=treatment |indication=Moderate to severe active rheumatoid arthritis, Active psoriatic arthritis, Moderate to severe atopic dermatitis, Moderate to severe ulcerative colitis, Moderate to severe active Crohn's disease, Active ankylosing spondylitis, and Active non-radiographic axial spondyloarthritis. |hasBlackBoxWarning=Y...")
- 20:3020:30, 9 March 2025 Fedratinib (hist | edit) [6,628 bytes] Omid Afkhami-Ardakani (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Omid Afkhami-Ardakani |genericName=Fedratinib |aOrAn=a |drugClass=Janus Kinase 2 (JAK2) Inhibitor |indicationType=treatment |indication=adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF). |hasBlackBoxWarning=Yes |adverseReactions=Diarrhea, Nausea, Vomiting, Fatigue, Anemia, Thrombocytopenia, Elevated liver enzymes (ALT/AST), and Elevated...")
13 February 2025
- 02:4702:47, 13 February 2025 Inavolisib (hist | edit) [24,016 bytes] Parth Vikram Singh (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |genericName=Inavolisib |aOrAn=a |drugClass=phosphoinositide 3-kinase inhibitors |indicationType=treatment |indication=Inavolisib is a phosphoinositide 3-kinase inhibitor that is FDA approved for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer Breast cancer,...")
12 February 2025
- 10:5610:56, 12 February 2025 Zenocutuzumab-zbco (hist | edit) [7,445 bytes] Nehal Eid (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |aOrAn=a |drugClass=HER2-and HER3-directed antibody |indicationType=treatment |indication=It is a bispecific HER2-and HER3-directed antibody indicated for the treatment of: • Adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.* • Adults with advanced, unresectable or metastatic pancreatic adenocarc...")
- 10:2010:20, 12 February 2025 Cosibelimab-ipdl (hist | edit) [6,051 bytes] Nehal Eid (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Nehal Eid |aOrAn=a |drugClass=programmed death ligand-1 (PD-L1) blocking antibody |indicationType=treatment |indication=It is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. |adverseReactions=The most common adverse reactions (≥10%) were fatigue, musculoskeletal pain, rash, diarrhea,...")
- 09:5609:56, 12 February 2025 Ensartinib (hist | edit) [6,265 bytes] Nehal Eid (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Nehal Eid |aOrAn=a |drugClass=Kinase inhibitor |indicationType=treatment |indication=It is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor. |adverseReactions=Most common adverse reactions (incidence≥20%) were rash, musculoskeletal pain, constipation, pruritus, cough, nause...")